Sutro Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.

News Market Reaction – STRO

+2.80%

+2.80% Session move

In the trading session that priced this news, STRO gained 2.80%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.

Conference Details:

The Citizens Life Sciences Conference
Date: May 7-8, 2025
Location: New York, NY

BofA Securities 2025 Health Care Conference
Date: May 13-15, 2025
Location: Las Vegas, NV

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.

About Sutro Biopharma
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF^®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

What investor conferences will Sutro Biopharma (STRO) attend in May 2025?

Sutro Biopharma will attend The Citizens Life Sciences Conference (May 7-8) in New York and the BofA Securities 2025 Health Care Conference (May 13-15) in Las Vegas.

How can investors access Sutro Biopharma's (STRO) conference presentations?

Investors can access the webcasts through the News & Events page of Sutro's Investor Relations section at www.sutrobio.com, with replays available for at least 30 days after each event.

What is Sutro Biopharma's (STRO) main business focus?

Sutro Biopharma is an oncology company that specializes in pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Where will the BofA Securities 2025 Health Care Conference featuring Sutro Biopharma take place?

The BofA Securities 2025 Health Care Conference will take place in Las Vegas, NV from May 13-15, 2025.